ArticleJournal of diabetes investigation2018
Plasma interleukin-22 levels are associated with prediabetes and type 2 diabetes in the Han Chinese population.
Article in Journal of diabetes investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- Circulating Interleukin-22 Is a Biomarker for Newly Diagnosed Type 2 Diabetes Mellitus and Associated with Hypoglycemic Effect of Sitagliptin.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Interleukin-22/Interleukin-22 binding protein axis and oral contraceptive use in polycystic ovary syndrome.Endocrine · 2023Article
- Temporal response characterization across individual multiomics profiles of prediabetic and diabetic subjects.Scientific reports · 2022Article
- Type 2 Diabetes Mellitus and Latent Tuberculosis Infection Moderately Influence Innate Lymphoid Cell Immune Responses in Uganda.Frontiers in immunology · 2021Article
- Longitudinal Analysis of Serum Cytokine Levels and Gut Microbial Abundance Links IL-17/IL-22 WithDiabetes · 2020Article
- Remodeling adipose tissue inflammasome for type 2 diabetes mellitus treatment: Current perspective and translational strategies.Bioengineering & translational medicine · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionThe objective of the present study was to investigate the relationship between plasma interleukin-22 (IL-22) levels and prediabetes or type 2 diabetes, and search the relevance between plasma concentrations of IL-22 and selected diabetes risk factors in Chinese people. MATERIALS AND
methodsThe Han Chinese origin men and women participants were recruited in our study during a conventional medical checkup. Fasting plasma IL-22 levels were detected by enzyme-linked immunosorbent assay, and their relevance with selected diabetes risk factors was explored. Multiple logistic regression analysis was carried out to assess the odds ratio of impaired fasting glucose (IFG) and type 2 diabetes according to plasma IL-22 level.
resultsCompared with normal glucose participants (250 pg/mL [interquartile range 154-901]), the plasma IL-22 levels in IFG participants (185 pg/mL [interquartile range 145-414]) and type 2 diabetes participants (162 pg/mL [interquartile range 128-266]) were significantly lower (P < 0.05, P < 0.001, respectively). Correlation analysis showed that plasma concentrations of IL-22 were negatively associated with some diabetes risk factors, including body mass index, glucose, systolic blood pressure, diastolic blood pressure and triglyceride. Furthermore, the plasma concentrations of IL-22 showed a highly significant association with IFG and type 2 diabetes.
conclusionsIn Chinese subjects, the plasma concentration of IL-22 is profoundly associated with susceptibility to IFG and type 2 diabetes, and decreased plasma IL-22 level is a potential trigger of IFG and type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.